Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Minimed GroupMMED +2.08%15 EV-to-EBITDA is -53.42 as of Aug. 28, 2026. GuruFocus rates MMED with a GF Score™ of 15/100. The stock has 3 warning signs investors should review. Among 523 Medical Devices & Instruments companies, Minimed Group ranks worse than 191204.4% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Minimed Group's enterprise value is $5,449 Mil.
Minimed Group's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 was $-102 Mil. Therefore, Minimed Group's EV-to-EBITDA for today is -53.42.
The historical rank and industry rank for Minimed Group's EV-to-EBITDA or its related term are showing as below:
MMED'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -169.39 Med: -107.44 Max: 70.14
Current: -53.42
During the past 4 years, the highest EV-to-EBITDA of Minimed Group was 70.14. The lowest was -169.39. And the median was -107.44.
MMED's EV-to-EBITDA is ranked worse than 100% of 523
companies
in the Medical Devices & Instruments industry
Industry Median: 14.62
vs MMED: -53.42
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Minimed Group's PE Ratio (TTM) for today is calculated as:
Minimed Group's share price for today is $19.91.
Minimed Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.083.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Minimed Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Minimed Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Minimed Group EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Minimed Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Minimed Group's EV-to-EBITDA falls into.
Minimed Group's current Enterprise Value is $5,449 Mil.
Minimed Group's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-102 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Minimed Group (MMED) has a EV-to-EBITDA of -53.42 as of Aug. 28, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Minimed Group. According to the industry distribution chart, Minimed Group ranks #999999 out of 523 companies in the Medical Devices & Instruments industry.
Is Minimed Group's EV-to-EBITDA too high?
Minimed Group's current EV-to-EBITDA is -53.42. Based on the distribution chart, Minimed Group ranks #999999 out of 523 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Minimed Group has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Minimed Group's EV-to-EBITDA compare to MMSI and NVST?
According to the Medical Devices & Instruments industry distribution chart, Minimed Group ranks #999999 out of 523 companies for EV-to-EBITDA. This places Minimed Group in the lower half of its industry. The industry median EV-to-EBITDA is 14.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.62, based on 523 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Minimed Group. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Minimed Group's current EV-to-EBITDA is -53.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minimed Group stock overvalued right now?
Minimed Group (MMED) has a current EV-to-EBITDA of -53.42. The current EV-to-EBITDA is -53.42. Minimed Group's overall GF Score™ is 15/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Minimed Group (MMED), the current EV-to-EBITDA is -53.42 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.
15GF Score
Get the complete analysis for MMED
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MMED has been successfully added to your 
